Ariel Global Fund stated the following regarding Sanofi (NASDAQ:SNY) in its Q3 2024 investor letter: "French pharmaceutical company, Sanofi (NASDAQ:SNY) was another contributor over the quarter as ...
RFK Jr. has developed a reputation as a vaccine skeptic and pushed conspiracy theories including one linking vaccines to ...
13d
Today, Sanofi and Breakthrough T1D UK announce a special collaboration with Beano, to mark World Diabetes Day, 14th November ...
The current US Supreme Court has no fundamental understanding of a range of medical, engineering, technological, or ...
Sanofi’s BTK inhibitor rilzabrutinib helped 23% of adults with a rare autoimmune blood disorder achieve target platelet counts in a Phase 3 trial, compared to … ...
Sanofi has released phase 3 data from the LUNA 3 trial of rilzabrutinib that should spark some buyer’s delight. The drug, which the French pharma giant acquired through a $3.7 billion buyout of ...
In October 2023, Sanofi announced plans to separate its consumer health unit in 2024. Sanofi’s consumer health division, with flagship products like Doliprane and Allegra, has been a reliable ...
For elderly people and those who already have chronic background diseases with weakened immunity, facing influenza can be self-threatening. On October 9, Sanofi and Vietnam Vaccine JSC (VNVC), the ...
On October 21, 2024, Sanofi (NASDAQ: SNY US (ADR), $53.83, Market Cap: $136.6 billion, EN Paris: SAN FP, €100.04, Market Cap: €126.9 billion) announced that it has entered into exclusive ...
Powered by PandaOmics, Insilico’s proprietary generative biology AI platform, the joint R&D team comprising Insilico Medicine and Sanofi colleagues focused on highly novel targets known to be ...
French pharma giant Sanofi is selling off its consumer healthcare business Opella. US-based investment firm Clayton, Dubilier & Rice (CD&R) is to take a controlling 50% stake, while Sanofi will retain ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback